Diagnosis of Nonalcoholic Steatohepatitis: Noninvasive Tools and Predictive Models
Released On
January 6, 2023
Expires On
January 6, 2024
Media Type
Internet
Completion Time
45 minutes
Specialty
Cardiology, Endocrinology, Gastroenterology, Hepatology, Nephrology, Nutrition, Pharmacy, Primary Care, Radiology
Topic(s)
Cardiovascular Disease, Diabetes, Heart, Nutrition, Obesity, Liver Disease, NAFLD, NASH
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Global Education Group and the Fatty Liver Foundation.
This activity is supported by an educational grant from Pfizer, Inc.
This activity is distributed by Applied Clinical Education and CMEZONE.COM.
Credit Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of primary care physicians, gastroenterologists, endocrinologists, diabetologists, hepatologists, obesity specialists, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with nonalcoholic steatohepatitis (NASH) or at risk for NASH.
Program Overview
Because NASH is under-recognized, clinician awareness of many elements of this illness is suboptimal. These elements include the clinical manifestations and disease burden; diagnostic approaches for suspected NASH, including investigational noninvasive diagnostic tools; and predictive models that may identify patients at risk for progression to severe liver disease. The goal of this program is to educate clinicians about the use of noninvasive diagnostic tools and predictive models to identify patients in need of treatment for NASH.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the epidemiology of NASH, including risk factors and health outcomes.
- Explain the historic approach to NASH diagnosis.
- Describe newer noninvasive tools for the diagnosis and ongoing monitoring of NASH.
- Review predictive models for the identification of patients with NASH who are at risk for advanced liver disease.
Faculty
Jeffrey T. Budd, MD
Associate Professor
Department of General Internal Medicine
The University of Florida
Gainesville, FL
Kenneth Cusi, MD
Professor of Medicine
Division of Endocrinology, Diabetes and Metabolism
The University of Florida
Gainesville, FL
John M. Vierling, MD
Professor of Medicine, Chief of Hepatology
Director, Baylor Liver Health
Section of Gastroenterology and Hepatology
Director, Advanced Liver Therapies
Professor of Surgery
Division of Abdominal Transplantation
Baylor College of Medicine
Houston, TX
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Fatty Liver Foundation (FLF). Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationships
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
| Name of Faculty or Presenter | Reported Financial Relationship |
|---|---|
| Jeffrey T. Budd, MD | Nothing to disclose |
| Kenneth Cusi, MD |
|
| John Moore Vierling, MD |
|
The planners and managers have the following relevant financial relationships with ineligible companies:
| Name of Planner or Manager | Reported Financial Relationship |
|---|---|
| Lindsay Borvansky | Nothing to disclose |
| Andrea Funk | Nothing to disclose |
| Liddy Knight | Nothing to disclose |
| Ashley Cann | Nothing to disclose |
| Lauren Sinclair | Nothing to disclose |
| Jennifer Kulpa | Nothing to disclose |
| Lance Azzo | Nothing to disclose |
| Henry E. Chang | Nothing to disclose |
| Wayne Eskridge | Nothing to disclose |
Instructions for Participation and Credit
To receive CME credit, participants must read the preamble, participate in the activity, complete and pass the post-test with a score of at least 75%, and complete the evaluation. CME certificates will be made available immediately upon successful completion.
Course Viewing Requirements
PC
- 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
- Windows 10, 8.1 (32-bit/64-bit); Windows 7 (32-bit/64-bit) 512 MB of RAM (1 GB recommended)
- Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
- For HTML Client – Google Chrome (v70.0 and above), Mozilla Firefox (v65.0 and above), and Edge (v42.0 and above)
MAC
- 1.83 GHz Intel Core Duo or faster processor 512 MB of RAM (1 GB recommended)
- MAC OS X 10.12, 10.13, and 10.14
- Mozilla Firefox, Apple Safari, Google Chrome
- For HTML Client – Google Chrome (v70.0 and above), Apple Safari (v12.0 and above), and Mozilla Firefox (v65.0 and above)
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and FLF do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.